Syndax Pharmaceuticals, Inc.
SNDXStock
$22.71+155.37%52W
Market Cap$2.03B
P/E—
Div yield—
Beta0.35
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-3.08%
Price vs S&P 500 (4W)26.20%
VGM Score60.47
Market Capitalization$2.03B
Earnings Surprise History
Q1 26-0.48est. -0.59
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.35
4.35
4.35
4.35
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SNDXSyndax Pharmaceuticals, Inc. | D | A | B | $22.71 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cancer and immune-related diseases. Its pipeline includes revumenib, a selective menin-MLL inhibitor for acute leukemias; axatilimab, a CSF-1R antibody for chronic graft-versus-host disease and pulmonary fibrosis; and entinostat, an oral small molecule targeting cancer cells and immune cells. The company is based in the United States.